Results of the base-case analysis
| Treatment | Cost | Incremental cost | QALY | Incremental QALY | ICER |
| FTD/TPI | US$32 234.26 | NA | 3.20 | NA | NA |
| Placebo | US$5378.6 | US$26 855.66 | 2.32 | 0.88 | US$30 494.89 |
FTD/TPI, trifluridine/tipiracil; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life year.